Novo Nordisk (NVO) stock is soaring Friday after the Danish pharmaceutical company reported positive early stage results for its once-weekly weight loss drug Amycretin.
The topline results from the Phase 1b/2a clinical trial showed that patients treated with Amycretin achieved a body weight loss of 9.7% in 20 weeks on 1.25 milligrams, 16.2% in 28 weeks on 5 milligrams and 22% in 36 weeks on 20 milligrams of the drug. Meanwhile, patients treated with the placebo experienced weight gains of 1.9%, 2.3% and 2%, respectively.
"We are very encouraged by the subcutaneous Phase 1b/2a results for Amycretin in people living with overweight or obesity," said Martin Lange, executive vice president for Development at Novo Nordisk. "The results seen in the trial support the weight lowering potential of this novel unimolecular GLP-1 and amylin receptor agonist, Amycretin, that we have previously seen with the oral formulation."
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Based on the positive results, Novo Nordisk said it is now planning further clinical development of the drug.
Is Novo Nordisk stock a buy, sell or hold?
Novo Nordisk has underperformed the broad market on the price charts over the past 12 months, down 17% vs the S&P 500's 27% gain. But Wall Street remains bullish on the healthcare stock.
According to S&P Global Market Intelligence, the average analyst target price for NVO stock is $113.44, representing implied upside of more than 30% to current levels. Additionally, the consensus recommendation is a Buy.
Financial services firm Argus Research is one of those firms with a Buy rating on NVO stock, along with a $110 price target.
"The company is working with regulators on new indications for its GLP-1 treatments and is also focused on launching new products," wrote Argus Research analyst Jasper Hellweg in a January 16 note. "On the fundamentals, the shares trade at 22 times our 2025 earnings-per-share estimate, well below the stock's five-year historical average of 31. Given the company's strong track record and growth outlook, we believe that a higher multiple is warranted."
Related Content
-
Seven Ways to Reduce Taxes on Social Security Benefits in 2025Social Security Minimizing taxes on Social Security is an essential consideration for many retirees.
-
Sherwin-Williams Is a Sleeper of the 100,000% Return ClubSherwin-Williams has quietly carved out a massive return for shareholders over the years.
-
Sherwin-Williams Is a Sleeper of the 100,000% Return Club
Sherwin-Williams has quietly carved out a massive return for shareholders over the years.
-
Want an Encore Career in Retirement? Consider These Seven StepsBurnout, a need for a change and/or a desire to stay engaged often propel people to start a new professional chapter. This is how you can do it.
-
How Federal Retirees Can Make SSFA Repeals Work for ThemFrom higher Social Security benefits to increased spousal and survivor benefits, federal employees have much to gain from the Social Security Fairness Act.
-
M&A Is Why UnitedHealth Group Stock Is in of the 100,000% Return ClubUnitedHealth has given a master class in mergers and acquisitions over the years.
-
How to Invest in the Nuclear RevolutionAccording to Energy Secretary Chris Wright, "The long-awaited American nuclear renaissance must launch during President Trump's administration."
-
How to Avoid These Five Costly Tax Mistakes That Many Retirees MakeMaking incorrect assumptions about tax brackets, tax-loss harvesting, charitable giving, estate taxes and more can cost you big-time in retirement.
-
Are You a Baby Boomer With $500,000 or Less Saved for Retirement?Here are seven ideas Baby Boomers can consider to help make the most of their financial resources for retirement.
-
Social Security Fairness Act Adds to Pressure on Safety NetWhile the law seeks to level the playing field for many federal employees, the sustainability of the Social Security system is now facing even more challenges.
